Omnicomm Systems Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
3,573.90
4,871.90
2,222.60
101.90
2,967.20
3,688
Depreciation, Depletion & Amortization
238.00
281.00
274.10
340.20
358.20
736.40
Other Funds
1,233.40
1,179.70
2,754.60
3,171.00
199.30
2,421.10
Funds from Operations
2,102.40
3,411.20
257.90
3,613.20
3,524.60
2,003.30
Changes in Working Capital
351.40
2,182.30
914.80
1,095.30
2,658.80
784.20
Net Operating Cash Flow
2,453.80
1,228.90
656.90
2,517.80
865.90
1,219.10
Capital Expenditures
353.80
101.50
450.70
260.40
242.40
Net Investing Cash Flow
740.30
101.50
450.70
260.40
242.40
Issuance/Reduction of Debt, Net
3,500.00
743.60
125.00
1,745.00
1,070.00
Net Financing Cash Flow
3,500.00
743.60
152.30
1,615.50
879.80
Net Change in Cash
287.40
743.00
235.90
597.80
243.00
Free Cash Flow
2,807.50
1,330.40
206.20
2,257.50
623.50
Net Assets from Acquisitions
386.50
-
-
-
-
Change in Capital Stock
-
-
27.30
129.50
190.30
Exchange Rate Effect
18.50
156.20
122.50
44.20
13.30

About Omnicomm Systems

View Profile
Address
2101 West Commercial Boulevard
Fort Lauderdale Florida 33309
United States
Employees -
Website http://www.omnicomm.com
Updated 07/08/2019
OmniComm Systems, Inc. engages in the provision of software solutions in the field of sciences. It supports customers through innovative technologies in management of risks, regulatory compliance, and clinical operations in the field of pharmaceutical, biotechnology, contract research organizations, diagnostic and device firms, and academic medical centers. Its products include 21 CFR Part 11 designed to offer clinical trial sponsors the ability to conduct clinical trials under multiple platforms.